SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 211 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 3.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,397,579 | -13.3% | 50,692 | -5.4% | 0.00% | -50.0% |
| Q2 2023 | $1,611,156 | -3.7% | 53,598 | +16.0% | 0.00% | 0.0% |
| Q1 2023 | $1,673,355 | +2.4% | 46,187 | +0.8% | 0.00% | 0.0% |
| Q4 2022 | $1,634,578 | +6.6% | 45,825 | +1.1% | 0.00% | 0.0% |
| Q3 2022 | $1,533,000 | +17.7% | 45,305 | +0.6% | 0.00% | +100.0% |
| Q2 2022 | $1,302,000 | -27.0% | 45,054 | -18.4% | 0.00% | -50.0% |
| Q1 2022 | $1,783,000 | +16.3% | 55,194 | +5.0% | 0.00% | +100.0% |
| Q4 2021 | $1,533,000 | +10.8% | 52,584 | +1.2% | 0.00% | 0.0% |
| Q3 2021 | $1,384,000 | -21.9% | 51,940 | -9.7% | 0.00% | 0.0% |
| Q2 2021 | $1,771,000 | +26.7% | 57,521 | +7.8% | 0.00% | 0.0% |
| Q1 2021 | $1,398,000 | -63.6% | 53,370 | -65.0% | 0.00% | -50.0% |
| Q4 2020 | $3,839,000 | +7.1% | 152,594 | -11.3% | 0.00% | 0.0% |
| Q3 2020 | $3,585,000 | -19.3% | 171,988 | -8.0% | 0.00% | -33.3% |
| Q2 2020 | $4,440,000 | +47.1% | 186,972 | +11.4% | 0.00% | 0.0% |
| Q1 2020 | $3,019,000 | +103.4% | 167,775 | +168.3% | 0.00% | +200.0% |
| Q4 2019 | $1,484,000 | +7.1% | 62,537 | +24.1% | 0.00% | 0.0% |
| Q3 2019 | $1,385,000 | +35.1% | 50,375 | +62.6% | 0.00% | 0.0% |
| Q2 2019 | $1,025,000 | -35.8% | 30,986 | -32.0% | 0.00% | 0.0% |
| Q1 2019 | $1,596,000 | -23.7% | 45,565 | -27.6% | 0.00% | -50.0% |
| Q4 2018 | $2,092,000 | -40.9% | 62,959 | -10.4% | 0.00% | -33.3% |
| Q3 2018 | $3,538,000 | -27.0% | 70,276 | -13.2% | 0.00% | -40.0% |
| Q2 2018 | $4,847,000 | +26.3% | 80,981 | -3.4% | 0.01% | +25.0% |
| Q1 2018 | $3,839,000 | +56.8% | 83,798 | +36.4% | 0.00% | +100.0% |
| Q4 2017 | $2,448,000 | -15.8% | 61,449 | -15.5% | 0.00% | -33.3% |
| Q3 2017 | $2,908,000 | +18.6% | 72,719 | +27.9% | 0.00% | +50.0% |
| Q2 2017 | $2,452,000 | +0.9% | 56,872 | -26.8% | 0.00% | 0.0% |
| Q1 2017 | $2,430,000 | +22.4% | 77,652 | -1.3% | 0.00% | 0.0% |
| Q4 2016 | $1,985,000 | -12.2% | 78,638 | -14.0% | 0.00% | 0.0% |
| Q3 2016 | $2,260,000 | +23.2% | 91,390 | +1.4% | 0.00% | 0.0% |
| Q2 2016 | $1,835,000 | +379.1% | 90,151 | +259.4% | 0.00% | – |
| Q1 2016 | $383,000 | -42.0% | 25,083 | -48.9% | 0.00% | -100.0% |
| Q4 2015 | $660,000 | +37.8% | 49,104 | +43.9% | 0.00% | 0.0% |
| Q3 2015 | $479,000 | -74.9% | 34,116 | -69.6% | 0.00% | -50.0% |
| Q2 2015 | $1,907,000 | +64.1% | 112,249 | +16.8% | 0.00% | +100.0% |
| Q1 2015 | $1,162,000 | -13.1% | 96,118 | -40.4% | 0.00% | 0.0% |
| Q4 2014 | $1,337,000 | +84.2% | 161,155 | +92.7% | 0.00% | 0.0% |
| Q3 2014 | $726,000 | +250.7% | 83,627 | +341.7% | 0.00% | – |
| Q2 2014 | $207,000 | -72.7% | 18,935 | -77.7% | 0.00% | -100.0% |
| Q1 2014 | $757,000 | +11.2% | 84,727 | -6.2% | 0.00% | 0.0% |
| Q4 2013 | $681,000 | -6.5% | 90,308 | -9.1% | 0.00% | 0.0% |
| Q3 2013 | $728,000 | +395.2% | 99,308 | +278.2% | 0.00% | – |
| Q1 2013 | $147,000 | – | 26,260 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |